Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Sep 6–Sep 13, 2026)

· 1 min read

No FDA decision dates or earnings reports fall in this week. The nearest regulatory events on the Run-up Radar are NUVL’s NDA decision in 12 days and MIRM’s in 20 days. Among last week’s biotech gainers, SMMT rose 17% on 2.9 times its average volume.

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • OSTX: Phase 1, Recruiting in 10 days, score 67/100
  • NUVL: NDA in 12 days, score 61/100
  • MIRM: NDA in 20 days, score 54/100

📈 Last Week’s Biggest Gainers

  • SMMT +17.33% (volume 2.9x average)
  • HCM +17.19% (volume 9.2x average)

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.